NCT06710197 2026-03-05
OZM-034
University Health Network, Toronto
Phase 2 Withdrawn
Clinical Trials
25 trialsNCT04205838 2026-02-27
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02021422 2026-02-18
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy
Baylor Research Institute
Phase 1 Completed
NCT05013450 2025-12-17
Dupilumab_Metastatic NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
NCT04148430 2025-11-05
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04359784 2025-10-23
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT06703216 2025-06-15
PACER
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Not yet recruiting
NCT04942626 2025-02-21
ACO/ARO/AIO-21
Goethe University
Phase 1 Completed
NCT04432506 2025-01-28
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03233776 2024-11-18
AFFECT-1
Radboud University Medical Center
Phase 2 Completed
NCT04099901 2024-11-18
AFFECT-2
Radboud University Medical Center
Phase 2 Completed
NCT03430011 2024-05-24
EVOLVE
Juno Therapeutics, a Subsidiary of Celgene
Phase 1/2 Completed
NCT02090101 2023-10-17
IRAFU
Centre Georges Francois Leclerc
Phase 2 Completed
NCT04227275 2023-08-21
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Tceleron Therapeutics, Inc.
Phase 1 Terminated
NCT01802970 2021-10-08
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Baylor Research Institute
Phase 1 Completed
NCT02550327 2021-06-22
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
Baylor Research Institute
Phase EARLY_PHASE1 Completed
NCT04691765 2021-03-19
Anakinra
Sunnybrook Health Sciences Centre
Phase 1 Unknown
NCT01624766 2021-02-25
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03578497 2021-01-27
FertIL
University Hospital, Basel, Switzerland
Phase 2 Completed
NCT02492750 2020-03-25
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT02326376 2020-01-18
Kineret CAPS Post Authorisation Study
Swedish Orphan Biovitrum
Completed
NCT00635154 2018-06-07
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT00072111 2015-04-30
Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene
National Cancer Institute (NCI)
Phase 1 Completed
NCT00537667 2009-11-26
The SPECTRA Study
Swedish Orphan Biovitrum
Phase 2 Terminated